Trial Profile
A Double-blind, Randomized, Placebo-controlled, 4-Period Cross-over Study to Evaluate the Effect of JNJ-53718678 on the Cardiac Repolarization Interval in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Rilematovir (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 17 Feb 2020 Status changed from recruiting to completed.
- 17 Oct 2019 Planned End Date changed from 14 Oct 2019 to 9 Dec 2019.
- 17 Oct 2019 Planned primary completion date changed from 20 Sep 2019 to 9 Dec 2019.